Losartan vs Amlodipine: Head-to-Head Efficacy Comparison

Why No Direct Head-to-Head Trial Exists

Losartan and amlodipine belong to different drug classes with different mechanisms, and both reached the market in the early 1990s when atenolol and thiazides served as standard comparators. Large outcomes trials for each drug (LIFE for losartan, ASCOT-BPLA for amlodipine) used beta-blocker-based regimens as control arms rather than comparing the two drugs against each other.

Different Mechanisms, Different Comparators

Losartan blocks the angiotensin II type 1 (AT1) receptor, reducing vasoconstriction and aldosterone secretion. Amlodipine inhibits L-type calcium channels in vascular smooth muscle, directly relaxing arterial walls. Because these mechanisms are complementary, the 2018 ESC/ESH hypertension guidelines actually recommend combining an ARB with a calcium channel blocker as one of the preferred initial two-drug strategies. That recommendation itself reflects the clinical reality: these drugs were designed to work together, not to compete.

Network Meta-Analysis Evidence

In the absence of a direct randomized comparison, clinicians rely on network meta-analyses. A 2015 Cochrane review of first-line antihypertensives (N=55 trials, 195,267 patients) found that calcium channel blockers and ARBs produced similar reductions in total mortality, though CCBs showed a slight edge in stroke prevention and ARBs showed lower rates of heart failure hospitalization. These indirect comparisons carry wider confidence intervals than a direct trial would, so the magnitude of any difference remains uncertain.

Blood Pressure Lowering: Amlodipine Has a Modest Edge

At standard starting doses (losartan 50 mg vs amlodipine 5 mg), amlodipine produces roughly 2 to 4 mmHg greater systolic blood pressure reduction. This difference is consistent across multiple trials and is clinically relevant at the population level, even if it appears small for an individual patient.

Dose-Response Curves

A 2003 meta-analysis in the American Journal of Hypertension pooled 354 randomized trials and found that amlodipine 5 mg lowered SBP by approximately 10 mmHg from baseline, while losartan 50 mg lowered SBP by approximately 7 to 8 mmHg. Doubling amlodipine to 10 mg added another 2 to 3 mmHg of reduction. Doubling losartan to 100 mg added approximately 1 to 2 mmHg. The dose-response curve for amlodipine is steeper.

24-Hour Ambulatory Monitoring

Both drugs provide true 24-hour coverage with once-daily dosing. A crossover study published in the Journal of Hypertension (2002) measured ambulatory blood pressure in 40 patients and found that amlodipine 5 mg maintained a lower nighttime SBP trough than losartan 50 mg by 3.1 mmHg (P=0.02). For patients whose office BP is controlled but whose nighttime readings remain elevated, this trough difference may tip the decision toward amlodipine.

When the Numbers Mislead

Raw BP reduction does not always predict outcomes. In LIFE, losartan reduced stroke risk by 25% compared to atenolol despite similar blood pressure reductions in both arms [1]. That stroke benefit appeared to be independent of BP lowering, suggesting that AT1 receptor blockade confers protection through mechanisms like reduced vascular remodeling and lower uric acid levels.

Cardiovascular Outcomes: What LIFE and ASCOT-BPLA Actually Showed

These two landmark trials are the most frequently cited when comparing losartan and amlodipine, but neither trial tested one drug against the other. Interpreting them side by side requires caution.

The LIFE Trial (2002)

The Losartan Intervention For Endpoint reduction trial enrolled 9,193 patients aged 55 to 80 with hypertension and electrocardiographic left ventricular hypertrophy (LVH). Patients were randomized to losartan-based or atenolol-based treatment and followed for a mean of 4.8 years [1].

Results were striking. The losartan arm saw a 13% reduction in the composite primary endpoint of cardiovascular death, stroke, or myocardial infarction (HR 0.87, 95% CI 0.77 to 0.98, P=0.021). Stroke reduction drove most of the benefit: a 25% relative risk reduction (P=0.001). New-onset diabetes was 25% less frequent with losartan. The LIFE investigators concluded that losartan provided benefits "beyond blood pressure reduction" in this high-risk LVH population.

The ASCOT-BPLA Trial (2005)

The Anglo-Scandinavian Cardiac Outcomes Trial, Blood Pressure Lowering Arm randomized 19,257 patients with hypertension and at least three additional cardiovascular risk factors to amlodipine-based or atenolol-based therapy [2]. The trial was stopped early at a median of 5.5 years because of clear differences favoring the amlodipine arm.

Amlodipine-based treatment reduced all-cause mortality by 11% (P=0.025), stroke by 23% (P=0.0003), and total cardiovascular events by 16% (P < 0.001). Blood pressure was 2.7/1.9 mmHg lower in the amlodipine arm, and investigators acknowledged that some of the outcome difference could be attributed to this BP gap.

Why You Cannot Simply Compare These Trials

The patient populations differed. LIFE required LVH at baseline. ASCOT-BPLA required three or more cardiovascular risk factors but not necessarily LVH. The control arms differed (atenolol alone in LIFE vs atenolol plus bendroflumethiazide in ASCOT). The add-on therapies differed (hydrochlorothiazide in LIFE vs perindopril in ASCOT). Drawing a direct efficacy comparison between losartan and amlodipine from these trials is an ecological fallacy.

Organ-Specific Outcomes: Where Each Drug Excels

The choice between losartan and amlodipine often comes down to what else is happening beyond blood pressure. Each drug has distinct advantages for specific organ systems.

Kidney Protection

Losartan holds an FDA-approved indication for delaying the progression of diabetic nephropathy. The RENAAL trial (N=1,513) demonstrated that losartan 50 to 100 mg reduced the risk of doubling serum creatinine by 25% and end-stage renal disease by 28% compared to placebo in patients with type 2 diabetes and nephropathy [3]. Amlodipine has no comparable renal outcomes data. For patients with proteinuria exceeding 300 mg/day, guidelines from the Kidney Disease: Improving Global Outcomes (KDIGO) group recommend an ARB or ACE inhibitor as first-line therapy.

Stroke Prevention

Both drugs reduce stroke risk, but the populations studied differ. The 25% stroke reduction in LIFE was specific to patients with LVH [1]. The 23% stroke reduction in ASCOT-BPLA applied to a broader high-risk hypertensive population [2]. A 2009 Lancet meta-analysis by Law et al. (N=147 trials, 464,000 participants) found that calcium channel blockers reduced stroke risk by an additional 10% beyond what would be expected from their BP-lowering effect alone, while ARBs showed no such extra benefit. This suggests amlodipine may have a slight edge for pure stroke prevention in patients without LVH.

Heart Failure

ARBs, including losartan, have a track record in heart failure management. The HEAAL trial (N=3,846) showed that high-dose losartan (150 mg) reduced heart failure hospitalizations by 13% compared to 50 mg in patients with reduced ejection fraction [4]. Amlodipine is not contraindicated in heart failure (unlike some other CCBs), but it does not improve heart failure outcomes. The PRAISE trial confirmed that amlodipine is safe in heart failure but does not reduce mortality. For patients with concurrent hypertension and HFrEF, losartan is the more logical first choice.

Coronary Artery Disease

Amlodipine has stronger evidence in stable angina. The CAMELOT trial (N=1,991) demonstrated that amlodipine 10 mg reduced cardiovascular events by 31% compared to placebo in patients with angiographically documented coronary disease and normal blood pressure [5]. IVUS imaging showed that amlodipine slowed atherosclerosis progression. No comparable coronary-specific outcomes trial exists for losartan.

Side Effect Profile: A Practical Differentiator

Efficacy discussions often overshadow tolerability, but side effects drive real-world adherence. The side effect profiles of these two drugs differ sharply.

Amlodipine Side Effects

Peripheral edema is the dominant concern. In ASCOT-BPLA, ankle swelling occurred in 23% of the amlodipine arm [2]. Rates in clinical practice typically range from 5 to 10% at 5 mg and 10 to 15% at 10 mg. The edema is dose-dependent and caused by precapillary arteriolar dilation, not fluid retention. It does not respond to diuretics. Other common effects include headache (7%), dizziness (3%), and flushing (2%).

Losartan Side Effects

Losartan is one of the best-tolerated antihypertensives. In LIFE, the discontinuation rate for adverse events was nearly identical between losartan and atenolol groups [1]. Dizziness occurs in approximately 3% of patients. Hyperkalemia risk exists but is low in patients with normal renal function (serum potassium rise of 0.1 to 0.3 mEq/L). Losartan is absolutely contraindicated in pregnancy, as all RAAS inhibitors carry teratogenic risk. Angioedema is rare (0.1%) but possible.

Adherence Implications

A 2019 retrospective cohort study in Hypertension (N=4.9 million) found that one-year adherence rates were highest for ARBs (55%) and lowest for diuretics (39%), with CCBs falling in between (50%). The modest adherence advantage of ARBs over CCBs correlates with their lower side effect burden. For a patient who has discontinued a previous antihypertensive due to side effects, losartan may be the safer bet for sustained adherence.

Who Should Get Which Drug

Guidelines do not declare either drug superior across all patients. The choice depends on the clinical scenario.

Choose Losartan When

The patient has left ventricular hypertrophy (LIFE evidence), type 2 diabetic nephropathy with proteinuria (RENAAL evidence), heart failure with reduced ejection fraction, hyperuricemia (losartan is the only ARB with uricosuric properties, lowering serum uric acid by 0.5 to 1.0 mg/dL), or a history of CCB-related edema.

Choose Amlodipine When

The patient has isolated systolic hypertension requiring maximal BP reduction, stable coronary artery disease (CAMELOT evidence), Raynaud's phenomenon (vasodilatory benefit), or African American heritage, as the ALLHAT trial (N=33,357) showed CCBs outperform ACE inhibitors for stroke prevention in Black patients, and this class effect likely extends to ARBs vs CCBs [6].

Use Both Together

The 2018 ESC/ESH guidelines recommend starting most patients with stage 2 hypertension (SBP ≥160 mmHg) on two-drug combination therapy from day one [7]. An ARB plus CCB combination is one of the two preferred pairings (the other being ARB plus thiazide). The rationale: combining drugs from different classes produces additive BP lowering while the ARB counteracts CCB-induced ankle edema by reducing postcapillary venous pressure. A single-pill combination of losartan 50 mg/amlodipine 5 mg is available in several markets.

Comparing Cost and Access

Both losartan and amlodipine are available as inexpensive generics throughout the United States. GoodRx data shows losartan 50 mg (30 tablets) priced at $4 to $10 and amlodipine 5 mg (30 tablets) priced at $4 to $8 at most chain pharmacies. Neither drug requires prior authorization from commercial insurers, Medicare Part D, or Medicaid. Cost is rarely a deciding factor between these two medications.

Generic Availability

Losartan lost patent protection in 2010. Amlodipine's patent expired in 2007. Both have been available as generics for over 15 years, and manufacturing supply is stable with multiple FDA-approved producers.

Insurance Formulary Placement

Both drugs sit on Tier 1 (preferred generic) of virtually every major formulary in the US, including UnitedHealthcare, Cigna, Aetna, Blue Cross Blue Shield plans, and Humana Medicare Advantage. There is no cost-driven reason to prefer one over the other.

Switching Between Losartan and Amlodipine

Patients sometimes need to switch from one drug to the other due to side effects, inadequate BP control, or a change in comorbidity status. The transition is straightforward because the drugs work through independent pathways.

How to Switch Safely

Most clinicians start the new drug at a standard dose while tapering or discontinuing the old one. There is no pharmacokinetic interaction between losartan and amlodipine, so a brief overlap period is safe. A reasonable protocol: start the new drug on day 1, continue the old drug for 3 to 5 days to prevent rebound hypertension, then stop the old drug. Recheck blood pressure at 2 to 4 weeks.

When the Switch Fails

If a patient does not achieve target BP (<130/80 mmHg per 2017 ACC/AHA guidelines) on either drug alone at maximum dose, combining both is the next step [8]. A patient who "failed" losartan 100 mg and "failed" amlodipine 10 mg individually may respond well to losartan 50 mg plus amlodipine 5 mg together, because the combination addresses two separate physiologic drivers of elevated blood pressure.